PDCD1 and hepatocellular carcinoma: Our study demonstrated that icaritin is a glycolysis inhibitor and thus has the potential to be administered as an immune enhancer in HCC patients treated with immunotherapy, such as anti-programmed cell death protein 1 therapy.